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Summary
Chiral drugs are made up of molecules with the 
same chemical structure, but different 
three-dimensional arrangements. Modern 
manufacturing has enabled the development of 
products containing a single molecular 
arrangement. The development of these single 
enantiomers from chiral drugs is known as chiral 
switching. Enantiomers of the same drug can
have different pharmacodynamic and 
pharmacokinetic properties. This may translate 
into potential health benefits, such as an 
improved safety margin, if one of the enantiomers 
has more favourable therapeutic and 
pharmacokinetic characteristics. However, some 
chiral switching has resulted in unpredicted 
toxicity and the withdrawal of the enantiomer 
from the market or a halt in its development. Drug 
companies are increasingly using chiral switching 
as a marketing strategy, but before prescribers 
switch to single enantiomer drugs they should 
look for evidence from well-conducted clinical 
trials that shows the chiral switch is cost-effective 
and improves the outcomes for patients rather 
than patents.




Have you ever tried putting your left shoe on your right foot or 
your right glove on your left hand? Unless you intend to destroy 
the function of this apparel, you know you will not succeed. 
Your left and right hands and feet are non-superimposable 
mirror images of one another. Chemicals including drugs can 
behave in a similar way. Many drugs consist of a mixture of 
left- and right-handed molecules (enantiomers), but there is 
an increasing trend for the pharmaceutical industry to develop 
and market products containing only the left- or right-handed 
molecule.1 While many of these single enantiomer drugs (such  
Definitions and chemistry
If a drug has a centre of asymmetry (usually a carbon atom 
with four different substituents), then it can exist as two 
non-superimposable left-handed and right-handed mirror 
images, also known as enantiomers. A racemate is a mixture 
of equal amounts of these two enantiomers. Many drugs are 
marketed as racemates. They are said to be chiral drugs (from 
the Greek word for hand, cheir). 
There are different methods for naming enantiomers. The 
definitive way is to use the prefix (R)- (right hand) and (S)- (left 
hand). Other prefixes are (+) and (–) or D and L. An example is 
ibuprofen (Fig. 1) which, as marketed in Australia, contains an 
equal amount of (R)-ibuprofen and (S)-ibuprofen. 
Enantiomers have identical physical and chemical properties 
such as molecular weight, solubility and melting point. The only 
difference is their three-dimensional spatial configuration. 
Enantiomer: one of a pair of stereoisomers that are 
non-superimposable mirror images of 
one another and therefore have a different 
3-dimensional configuration
Isomers: compounds with the same molecular formula 
but with different 3-dimensional configuration 
Racemate: a mixture of two enantiomers, usually in 
one-to-one ratio
Fig. 1 
Ibuprofen is a racemic mixture of two non-superimposable 
mirror image enantiomers, (+)-(S)-ibuprofen and 
(–)-(R)-ibuprofen. The majority of the effects of racemic 
ibuprofen are elicited by (+)-(S)-ibuprofen.




as sertraline and salmeterol) are new chemical entities, others 
have been developed from currently marketed drugs which are 
a mixture of different enantiomers (racemates). For example, 
esomeprazole is an enantiomer of the racemate omeprazole. 
The term chiral switching has been coined to describe the 
development of single enantiomers from old racemate drugs.
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Most drugs obtained from nature are chiral, but in nature only 
the biologically active enantiomer is synthesised. For example, 
the poppy plant Papaver somniferum only synthesises the pain 
relieving (–)-(5R,6S,9R,13S,14R)-morphine. As morphine has a 
demanding chemical structure with five asymmetric centres, 
the technical difficulties and costs associated with chemically 
manufacturing large amounts for therapeutic use are such that 
it is more economically viable for companies to extract the 
morphine for the world market from poppies, rather than to 
artificially synthesise it. However, for many other chiral drugs, 
synthesis of the individual enantiomers is now economically 
feasible.
Pharmacodynamic differences between 
enantiomers
The interactions in the body between a drug and the proteins 
which elicit therapeutic or adverse effects and eliminate the 
drug require a specific three-dimensional configuration of drug 
and protein.
Since enantiomers have different three-dimensional 
configurations, the pharmacodynamics and pharmacokinetics 
of the two enantiomers which make up a racemic drug can be 
quite different. The differences often depend on whether the 
centre of asymmetry of the drug is in close proximity to the 
points of attachment to the protein. For example: 
  (S)-ibuprofen is over 100-fold more potent an inhibitor of 
cyclo-oxygenase I than (R)-ibuprofen
  (R)-methadone has a 20-fold higher affinity for the µ opioid 
receptor than (S)-methadone 
  (S)-citalopram is over 100-fold more potent an inhibitor of the 
serotonin reuptake transporter than (R)-citalopram. 
The so-called inactive enantiomer (one that has much less 
affinity for the drug's target site) is not necessarily an inert 
substance with no effects in vivo. For example, the cardiotoxicity 
of bupivacaine is mainly associated with the (R)-enantiomer, the 
psychomimetic effects of ketamine are more associated with the 
(R)-enantiomer, and (S)-baclofen antagonises the effects of 
(R)-baclofen. The beneficial effects of a drug can therefore reside 
in one enantiomer, with its paired enantiomer having: 
  no activity
  some activity 
  antagonist activity against the active enantiomer 
  completely separate beneficial or adverse activity from the 
active enantiomer. 
Pharmacokinetic differences between 
enantiomers
As the distribution and elimination of drugs from the 
body also involves their interaction with proteins, then the 
pharmacokinetics of enantiomers can also be different. For 
example:
  the bioavailability of (R)-verapamil is more than double that 
of (S)-verapamil due to reduced hepatic first-pass metabolism 
  the volume of distribution of (R)-methadone is double that of 
(S)-methadone due to lower plasma binding and increased 
tissue binding 
  the clearance of (R)-fluoxetine is about four times greater 
than (S)-fluoxetine due to a higher rate of enzyme 
metabolism 
  the renal clearance of (R)-pindolol is 25% less than 
(S)-pindolol due to reduced renal tubular secretion. 
These differences in clearance and volume of distribution 
translate into differences in half-life. For example the half-life
of (S)-fluoxetine is one quarter that of (R)-fluoxetine. In addition,
these pharmacokinetic properties can be modified in a 
stereoselective manner by disease, genetics, ethnicity, age and 
other drugs. Finally, the enantiomers of some drugs such as 
warfarin can be metabolised by different enzymes. 
Rationale for marketing chiral specific drugs
There are several possible health benefits to chiral switching. 
They include: 
  an improved safety margin (therapeutic index) through 
increased receptor selectivity and potency, and reduced 
adverse effects 
  a longer or shorter duration of action due to pharmacokinetic 
considerations (e.g. half-life) resulting in a more appropriate 
dosing frequency 
  decreased interindividual variability in response commonly 
due to polymorphic metabolism 
  decreased potential for drug-drug interactions. 
As some racemic drugs were patented without separate 
patents for each enantiomer, some companies have seized 
the opportunity to develop and market or license single 
enantiomers of marketed chiral drugs (for example an American 
company now markets (R)-salbutamol). Another commercially 
driven reason for chiral switches is the impending expiry of the 
patents of some 'blockbuster' racemic drugs. The manufacturers 
have developed and marketed the single enantiomer with 
a view to extending the patent franchise and protecting 
themselves from competitors who produce generic copies of 
the racemate.2 
Obtaining marketing approval for a chiral switch usually requires 
relatively few new studies to be conducted if the racemate 
is already marketed. The single enantiomer can be ready for 
launch before the patent for the racemate expires and before 
the marketing of any generics (which tend to substantially drive 
down the cost of the racemate). 
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Pros and cons of recent chiral switches 
Many single enantiomer chiral switches have recently received 
marketing approval in Australia or are likely to be submitted 
for approval. These include single enantiomers of omeprazole, 
bupivacaine, citalopram, ofloxacin, salbutamol, ketamine, 
methylphenidate, cetirizine and oxybutinin. In most cases, 
the manufacturer has claimed specific advantages over the 
racemate, particularly decreased incidences and severity of 
adverse effects. These claims need to be confirmed in clinical 
trials with sufficient power to show any clinically significant 
advantages. 
In some cases, chiral switching has been of no benefit. 
For example, the clinical development of (R)-fluoxetine for 
depression (based on a more acceptable half-life and less 
propensity for significant drug-drug interactions) was stopped 
because of a small but statistically significant prolongation of 
the QT interval with high doses. Dilevalol was thought to have 
advantages over labetalol, but was removed from the Japanese 
market because of hepatotoxicity.
Esomeprazole
A recent addition to the Pharmaceutical Benefits Scheme is 
esomeprazole, the (S)-enantiomer of omeprazole. All proton 
pump inhibitors exist as two inactive enantiomers (prodrugs) 
that are converted to active moieties which equally inactivate 
the H+/K+-ATPase pump. Both enantiomers of omeprazole are 
equipotent, however, their metabolism is different. 
(R)-omeprazole is mainly metabolised by the polymorphic 
CYP2C19 enzyme. There is a 7.5-fold difference in the systemic 
exposure to (R)-omeprazole in patients who are poor metabolisers 
compared to extensive metabolisers. With (S)-omeprazole 
this difference is reduced to about three-fold so it was argued 
that use of esomeprazole would be associated with less 
interindividual variability in efficacy. However, there are few data 
to support this theoretical advantage3, especially when only 3% of 
the Caucasian population are poor metabolisers. There may be 
a benefit in the Asian population where the incidence of poor 
metabolisers is about 20%. A rationale for chiral switching to 
esomeprazole might therefore be based on ethnic differences in 
metabolism. 
Escitalopram
The selective serotonin reuptake inhibitor activity of citalopram 
and its active metabolites resides mainly in the (S)-enantiomer. 
This enantiomer and its metabolites are eliminated slightly faster 
from the body than the (R)-enantiomer and its metabolites. In 
overdose, there is a concern about the potential for sudden 
death, possibly related to QT prolongation due to a secondary 
metabolite formed from (R)-citalopram. (S)-citalopram 
(escitalopram) was therefore developed with the aim of a better 
harm:benefit ratio compared to (R)-citalopram. However, this 
potential clinical advantage remains to be clinically proven. 
Conclusion 
Drug development is becoming longer and more complex, 
while marketing is increasingly competitive. Differences 
between single enantiomers and racemates are likely to 
become the focus for aggressive promotion of the  new’ 
entity. Regulatory authorities and independent sources of 
drug information (Australian Medicines Handbook, Australian 
Prescriber, Therapeutic Guidelines, National Prescribing Service) 
need to be provided with good evidence, from well-conducted 
clinical trials and appropriate pharmacoeconomic studies, that 
chiral switches have advantages for the prescriber and the 
consumer. The future will see not only more chiral switches but 
metabolite switches and metabolite-chiral switches providing 
fertile ground for patent lawyers and clinical pharmacologists.
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Self-test questions
The following statements are either true or false 
(answers on page 51)
9. The enantiomers which make up a racemate may not 
have identical biological effects.
10. Some enantiomers have no clinically significant 
advantages over the racemate they are part of.
’
